Welcome to LookChem.com Sign In|Join Free
  • or
HENAN SUNLAKE ENTERPRISE CORPORATION936563-96-1 C25H24N6O2 Ibrutinib//file1.lookchem.com/300w/synthetic/2022-02-06-06/045bc7e8-a484-4569-ac64-2f7e3e1ee93c.png
qq

Communicate with Supplier:

Ms. summer
Ms. summer: What can I do for you?

936563-96-1 C25H24N6O2 Ibrutinib CAS NO.936563-96-1

Min.Order Quantity:
1 Kilogram
Purity:
99%
Port:
Shanghai/Tianjin/Qingdao
Payment Terms:
L/C,D/A,D/P,T/T,

Add to Inquiry Cart

Product Details

Keywords

  • 4-phenoxyphenyl
  • pyrimidin
  • pyrazolo

Quick Details

  • ProName: 936563-96-1 C25H24N6O2 Ibrutinib
  • CasNo: 936563-96-1
  • Molecular Formula: C25H24N6O2
  • Appearance: As detailed
  • Application: 936563-96-1 ...
  • DeliveryTime: 7-10 days after payment
  • PackAge: As required
  • Port: Shanghai/Tianjin/Qingdao
  • ProductionCapacity: 100-200 Kilogram/Month
  • Purity: 99%
  • Storage: room temperature
  • Transportation: By air/sea/express
  • LimitNum: 1 Kilogram
  • Grade: Pharma Grade

Superiority

about certificate

1.certificate of analysis (coa)
2.material safety data sheet (msds)
3.route of synthesis (ros)
4.method of aanlysis(moa)
5.nuclear magnetic resonance(nmr)

about service

1. quality control, before shipment, free sample for test.
2. prompt shipment with professional documents
3. packing as your request, with photo before shipment
4. mixed containers with different mixed items in one container

about company

hennan sunlake enterprise corporation is located in henan province , the central plain of china , which enjoys favorable geogeaphical position and convenient transportion, the com[any was established in june. 1998 , until now having more than 18 years experience in manufacturing & exporting chemical raw material .
sunlake is a professional manufacturer engaged in producing and selling chemicals,including organic & inorganic chemicals , pigments & dyestuffs , water treatment chemicals , food & feed additives and others . these products have been being well exported to europe , southeast asia , the middle east , africa , south america and some other countries and areas.
we sincerely welcome foreign friends to visit our plant for cooperation. with the idea of "quality first,credit priority, excellent service", we are highly acknowledged by customers for good quality and competitive price. more importantly , the company has a strong r & d team, who are professional engineers and scholars with ph. d. .so we are confident to serve you better with our high - quality products and professional team.
we are taking great efforts to provide our customers with demanded goods and professional services, and continuously improve our core ability of competition and get the momentum for sustainable development, and finally make us being a reliable and professional wupplier in international market.
we welcome any serious inquiries from all customers of the world, and sincerely hope to cooperate with you for a brilliant future!

Details

product name: ibrutinib
synonyms: pci-32765;1-[(3r)-3-[4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one;pci-32765 (ibrutinib);(r)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one;1-[(3r)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3, 4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one;ibrutinib (pci-32765);1-{3-[4-amino-3-(4-phenoxy-phenyl)-pyrazolo[3,4-d]pyrimidin-1-yl]-piperidin-1-yl}-propenone;1-{3-[4-amino-3-(4-phenoxy-phenyl)-pyrazolo[3,4-d]pyrimidin-1-yl]-piperidin-1-yl}-but-3-en-1-one
cas: 936563-96-1
mf: c25h24n6o2
mw: 440.5
einecs:
product categories: inhibitor;inhibitors
mol file: 936563-96-1.mol
ibrutinib structure
ibrutinib chemical properties
density 1.34
safety information
msds information
ibrutinib usage and synthesis
bruton tyrosine kinase (btk) inhibitor ibrutinib is a kind of bruton tyrosine kinase (btk) inhibitor, it could be used for the treatment of chronic lymphocytic leukemia (cll) and mantle cell lymphoma (mcl). mcl and cll are belonged to the b-cell non-hodgkin's lymphoma, which is difficult to cure and easy to recurrent. common chemical immunotherapy does not have the targeting, often occurs 3 or 4 adverse reactions. ibrutinib and b lymphocytes could target with btk which is necessary for formation, differentiation, and transmission of information, inhibit btk activity irreversibly, and inhibit tumor cell proliferation and survival effectively. ibrutinib could be rapidly absorbed after oral administration, during 1 ~ 2h reach maximum blood concentration, adverse reactions belong to one or two, therefore, ibrutinib will become a new choice of treatment of cll and mcl.
food and drug administration (fda) of usa has speed up approval of pharmacyclics corporation and johnson & johnson's imbruvica (generic name: ibrutinib) came to market to the cure a kind of rarely aggressive leukemia - mantle cell lymphoma (mcl) in 13th november, 2013. ibrutinib is a new kind of oral bruton tyrosine kinase (btk) inhibitor, it was awarded by fda be a breakthrough drugs in february of 2013, and approved the mcl and cll treatments in 13th november, 2013 and 12th february, 2014 respectively. it could covalently bound selectively with cysteine residues (cys-481) in active site of btk target protein, irreversible inhibit btk, thereby effectively prevent tumor cells from migrating from b cell to lymphoid tissue where adapt for tumor growth. information was collated by xiaonan editor of chemicalbook.
chronic lymphocytic leukemia (cll) and mantle cell lymphoma (mcl) chronic lymphocytic leukemia (cll) is a kind of chronic hematological malignancies that because mature lymphocytes cannot apoptosis normally, but the clonal proliferation in lymphoid tissues.cll has some hereditary, it is a common form and belonged to non-hodgkin's lymphoma (nhl) of b cells. mantle cell lymphoma (mcl) is a rare b-cell nhl, 5% ~ 10% accounting for all the nhl, it has refractory and aggressive of malignant lymphoma. mcl is difficult to diagnose, approximately 85% patients are diagnosed at stage ⅲ ~ ⅳ, and easy to relapse,which is the lowest long-term survival of lymphoma subtypes. clinical manifestations are including high fever, fatigue, spleen and lymph nodes, infiltration of the gastrointestinal tract, and nervous system involvement.
at present, first-line treatment for cll is fcr program, which is combining fludarabine (f), cyclophosphamide (c), and rituximab (r). this program had positive effect, but the survival was 38% current first-line treatment for cll is fcr program that of the three joint regimen, the program has some effect, but the rate of progression-free survival was 38%, it happened 3 or 4 adverse reactions sometimes. mcl often used anthracycline or high-dose cytarabine-containing drugs, but mostly conventional chemotherapy is not sensitive. though there are many drugs for the treatment, survival was not significantly longer ; although the program is also used in combination with chemotherapy drugs and monoclonal antibody therapy mcl, high toxicity has made the infection rate is about 14%, 3 to 4 adverse reaction rates as high as 87%. therefore, coming up with more viable treatment programs and safe drugs are need to be introduced efficiently.
research and development process ibrutinib was developed by american celera genentech (celera genomics) that was well known because it was the first one drawn "human genome". pan zhengying (now beijing university shenzhen graduate school distinguished fellow) as the first author of this research and published the process of ibrutinib in 2007 (chemmedchem 2 (1): 58-61). but celera had transferred the development rights to pharmacyclics company of california due to funding and resources. although pharmacyclics company was in a very difficult stage, only $ 0.64 for the stock, facing delisting and bankruptcy in that time, company's management has managed to raise funds, spent only $ 2 million to down payment, 100 million shares and future sales royalty and milestone payment of royalties more to get ibrutinib. in 2011, johnson & johnson subsidiary janssen pay $ 150 million upfront payment in order to get the right to cooperate with pharmacyclics. once the new drugs in clinical trials and approved to listing, pharmacyclics company will get $ 975 million in total revenue, and they will share the sales.when the deal was announced, pharmacyclics stock is only $ 12. market value was only several hundred million dollars. however, the stock is already $ 123, $ 9.05 billion value now.
mechanism signaling pathway of b cell antigen receptor (bcr) is a key driver of tumor growth and spread. btk as an indispensable participant for bcr signal peptide, it is very important for formation, differentiation, messaging and survival of b lymphocyte. btk is an identifiable signal peptide molecules of bcr channel. when the signal peptide molecules across the b lymphocyte surface receptors, required channel is activated for transportation, chemotaxis and adhesion, which provide a convenience to be b-cell malignancies.
ibrutinib is a small molecule can selectively and covalently bound to a cysteine residue (cys-481) btk active site, and irreversibly inhibit btk activity, thereby inhibiting bcr activated signaling pathway, which could effectively prevent the tumor from b cells to lymphoid tissues where suitable for tumor growth, to reduce b cell proliferation and induce apoptosis of malignant cells, which play a role in the treatment of cll and mcl. non-clinical studies have shown that ibrutinib can inhibit malignant b lymphocyte proliferation and survival.
metabolism and elimination ibrutinib primarily metabolized by the cytochrome p450 (cyp3a and a small part of the cyp2d6) and produce a variety of metabolites after metabolism. the metabolite (pci-45227) is a kind of dihydrodiol substance which is an activity of inhibiting btk.compared with ibrutinib, pci-45227 has much stronger inhibition on btk, which is about 15 times stronger. at steady state, the average rate of metabolism of pci-45227 is around 1 ~ 2.8.
apparent clearance (cl / f) of ibrutinibis is approximately 1 000 l / h, the half-life (t1 / 2) is 4 ~ 6 h. ibrutinib mainly be metabolites in the body, excrete with the feces. to healthy subjects by oral radioactive 14c-labeled ibrutinib, found that nearly 90% of the radiation were eliminated in 168 h, most (about 80%) of them were excreted with the feces, and nearly 10% were excreted in the urine, about 1 % be prototypes were excreted with the feces.
elimination of ibrutinib will not make a difference in age (37 to 84 years) and gender, but systemic exposure of patients with moderate hepatic injury will be 6 times higher than in healthy subjects.
patents foreign patents: wo 2008039218 (compound); wo 2013003629 (purposes)
us patent number: 7,514,444, 7,718,662, patents is valid: december 2026
domestic patent: cn101610676a, cn101610676b, cn101805341a, cn101805341b, cn102746305a, cn102887900a
ibrutinib preparation products and raw materials

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)